Clinical Trials on EGFR and/or ROS Mutant NSCLC in South Africa
Total 23 results
-
AstraZenecaNo longer available
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationAustralia
-
University of SydneyAstraZeneca; Australasian Lung Cancer Trials GroupActive, not recruitingEGFR Mutant Advanced Non Small Cell Lung CancerTaiwan, Australia
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, Italy, Korea, Republic of, Canada, France, Australia, Germany, United Kingdom, Hong Kong, Turkey
-
Puma Biotechnology, Inc.TerminatedSolid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsFrance, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
-
PfizerCompletedLocally Advanced or Metastatic NRAS Mutant MelanomaUnited States, Australia, Germany, Italy, Netherlands
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
Novartis PharmaceuticalsTerminatedCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)Tumors With Aberrations in ALK or ROS1United States
-
Aesculap AGRaylytic GmbHRecruitingKnee Osteoarthritis | Osteonecrosis | Knee Arthritis | Instability, Joint | Rheumatoid Arthritis of Knee | Deformity Knee | Primary Osteoarthritis of Knee Nos | Secondary Osteoarthritis of Knee NosAustralia, Germany
-
Black Diamond Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...Korea, Republic of, United States
-
Genzyme, a Sanofi CompanyCompletedAlport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2France, Germany, Australia, United States, United Kingdom, Canada
-
Genentech, Inc.RecruitingMelanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCCKorea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
-
EMD SeronoMerck KGaA, Darmstadt, GermanyCompletedN-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous MelanomaUnited States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
-
BeiGeneActive, not recruitingNonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)United States, China, Korea, Republic of, France, Spain, Australia, Austria
-
PfizerNo longer availableNon Small Cell Lung Cancer ALK Positive or ROS1 PositiveUnited States
-
Apollomics Inc.RecruitingGastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 SkippingUnited States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
-
Oak Hill Bio LtdTerminatedIntraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)United States, Italy, United Kingdom
-
Aminex Therapeutics, Inc.RecruitingMelanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditionsUnited States, Australia
-
ArQule, Inc. (a wholly owned subsidiary of Merck...Worldwide Clinical TrialsTerminatedPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus SyndromeUnited States, Australia, Italy, Spain
-
Merck Sharp & Dohme LLCActive, not recruitingPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)United States, Australia, Brazil, Italy, United Kingdom
-
OHB Neonatology Ltd.Active, not recruitingIntraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)United States, United Kingdom, Italy, France, Germany, Netherlands, Finland, Japan, Portugal, Canada, Ireland, Spain, Sweden